National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies.
Phase of Trial: Phase IV
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors UCB
- 07 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2017.
- 07 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
- 10 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.